AMAG Pharmaceuticals, Inc. to Host Conference Call on March 5, 2012 at 4:30 p.m. ET to Discuss Financial Results for the Fourth Quarter and Year Ended 2011

LEXINGTON, Mass.–(BUSINESS WIRE)–Feb. 23, 2012–
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report
audited consolidated financial results for the fourth quarter and year
ended December 31, 2011 after the U.S. financial markets close on March
5, 2012. The announcement will be followed by a conference call and
webcast with slides at 4:30 p.m. ET during which management will discuss
the company’s financial results, commercial progress and development
programs.

To access the conference call via telephone, please dial (877) 412-6083
from the United States or (702) 495-1202 for international access. A
telephone replay will be available from approximately 8:30 p.m. ET on
March 5, 2012 through midnight March 9, 2012. To access a replay of the
conference call, dial (855) 859-2056 from the United States or (404)
537-3406 for international access. The pass code for the live call and
the replay is 56349072.

The call will be webcast with slides and accessible through the
Investors section of the Company’s website at www.amagpharma.com.
The webcast replay will be available from approximately 8:30 p.m. ET on
March 5, 2012 through midnight April 5, 2012.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
development and commercialization of a therapeutic iron compound to
treat iron deficiency anemia. AMAG manufactures and sells Feraheme®
(ferumoxytol) Injection for intravenous use. For additional company or
product information, please visit www.amagpharma.com
or http://feraheme.com.

Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.

Source: AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc.
Amy Sullivan, 617-498-3303